Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 6422 results found since Jan 2013.
Boningmycin induces AMPK-mediated endoplasmic reticulum-associated degradation of PD-L1 protein in human cancer cells
In conclusion, it is the first report demonstrating that BON decreases PD-L1 protein level through AMPK-mediated endoplasmic reticulum-associated degradation pathway. These findings will benefit the clinical transformation of BON and aid in the elucidation of molecular mechanism of BLM-related compounds.PMID:37717372 | DOI:10.1016/j.intimp.2023.110905
Source: International Immunopharmacology - September 17, 2023 Category: Allergy & Immunology Authors: Juan Zhang Jincai Wang Yue Shang Yang Chen Shuzhen Chen Qiyang He Source Type: research
Metformin inhibits self-renewal of colorectal cancer stem cells by inhibiting mitochondrial oxidative phosphorylation
CONCLUSION: Metformin reduces mitochondrial oxidative phosphorylation and ROS levels by inhibiting mitochondrial complex Ⅰ, thereby suppressing Wnt signaling pathway to reduce selfrenewal ability of colorectal CSCs.PMID:37712263 | PMC:PMC10505579 | DOI:10.12122/j.issn.1673-4254.2023.08.03
Source: Journal of Southern Medical University - September 15, 2023 Category: Universities & Medical Training Authors: C Yan S Liu Q Song Y Hu Source Type: research
SPIOMET4HEALTH —efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, fo ur-arm, parallel-group, phase II clinical trial
DiscussionThe present study will be the first to evaluate —in a randomised, double-blind, placebo-controlled way—the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention.Trial registrationEudraCT 2021 –003177-58. Registered on 22 December 2021.https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58.
Source: Trials - September 15, 2023 Category: Research Source Type: clinical trials
PLGA-based microspheres loaded with metformin hydrochloride: modified double emulsion method preparation, optimization, characterization, and in vitro evaluation
Ann Pharm Fr. 2023 Sep 12:S0003-4509(23)00105-0. doi: 10.1016/j.pharma.2023.09.002. Online ahead of print.ABSTRACTThe modified solvent removal method was used to encapsulate metformin hydrochloride (MH) within poly(lactic-co-glycolic acid) (PLGA) microspheres. The study investigated the effect of varying polymer concentrations on the loading and release of the drug from the microspheres. The encapsulation process involved using a double emulsion method, resulting in microspheres with particle diameters ranging from approximately 4.4 µm to 2.7 µm. The study achieved high encapsulation efficiencies, ranging from 81% to 90%...
Source: Annales Pharmaceutiques Francaises - September 14, 2023 Category: Drugs & Pharmacology Authors: Priyanka Chauhan Himanshu Paliwal Chetan Singh Chauhan Ankit Paliwal Source Type: research
Metformin combined with rapamycin ameliorates podocyte injury in idiopathic membranous nephropathy through the AMPK/mTOR signaling pathway
In conclusion, metformin combined with rapamycin decreased proteinuria, improved renal fibrosis and podocyte autophagy via AMPK/mTOR pathway in IMN rats. The metformin and rapamycin decreased proteinuria and inproved renal fibrosis in IMN model rats.PMID:37702819 | DOI:10.1007/s12079-023-00781-8
Source: Journal of Cell Communication and Signaling - September 13, 2023 Category: Molecular Biology Authors: Meichen Ma Yue Pan Yue Zhang Mei Yang Ying Xi Baoxu Lin Wudi Hao Jianhua Liu Lina Wu Yong Liu Xiaosong Qin Source Type: research
